Strategic Education, Inc. (Strategic Education) (NASDAQ: STRA) today announced financial results for the period ended December 31, 2020."We are encouraged...
- UPLIFT, a single-arm registration strategy evaluating upifitamab rilsodotin (UpRi) in platinum-resistant ovarian cancer, on track to begin in Q1...
VXA-CoV2-1 oral COVID-19 vaccine candidate targeting both the S and N proteins is planned to advance to Phase 2 testing...
Company demonstrates resilience despite COVID-19 challenges: Financial situation secure and development programs progressingConference call begins today at 4:30 p.m. (ET)BASKING...
2021 Vaccine Manufacturing: Raises lower end of global manufacturing plan for 2021 from 600 million doses to 700 million doses;...
– 2020 Highlights Include: Enrollment Completion of Pivotal PHYOX™2 Trial of Nedosiran for Primary Hyperoxaluria; Positive RG6346 Phase 1 Data...
- Initiated the Phase 2b SOOTHE clinical trial in refractory chronic cough; topline results expected Q4 2021 with an interim...
Passenger traffic continues to reflect travel disruptions worldwide due to the COVID-19 pandemicMEXICO CITY, Feb. 24, 2020 /PRNewswire/ -- Grupo...
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a...
2020 Net Revenues of $83.1 Million Increased 19% over 2019Fourth Quarter Net Revenues of $24.7 Million or $80 Per BottleNew...
SAN FRANCISCO, Feb. 25, 2021 /PRNewswire/ -- Marin Software Incorporated (NASDAQ: MRIN), a leading provider of digital marketing software for...
– NDA and MAA for odevixibat accepted, on track for anticipated H2 21 launch –– Announces odevixibat co-promotion agreement with...
- Outlined strategy to build integrated cell therapy company and the Company’s “2-2-5-2” five-year core value drivers -- Reported compelling...
Two Phase 3 trials, EMERGENT-2 and EMERGENT-4, initiated evaluating KarXT for the treatment of psychosis in adults with schizophreniaResults from...
Achieved 2020 financial guidance2021 guidance reflects increased investments in wholly owned pipeline to drive future revenue growthWebcast today, February 24,...
Conference Call and Webcast Scheduled for 5:00 p.m. Eastern TimeSangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported...
Feb 25 (Reuters) - The adhering to are the leading tales in the Financial Situations. Reuters has not verified these...
Achieved Oxbryta® (voxelotor) net revenues of $41.3 million in the fourth quarter and $123.8 million for full year 2020Further established...
